AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
DSS Subsidiary Impact BioMedical Announces Reverse Merger with Dr. Ashleys Limited
ByAinvest
Wednesday, Jun 25, 2025 6:58 am ET1min read
DSS, Inc.'s subsidiary Impact BioMedical Inc. has announced a strategic reverse merger with Dr. Ashleys Limited, a global pharmaceutical company. The combined entity will be listed on NYSE American as "Dr Ashleys Limited", with DSS retaining a 4.80% ownership. The merger aims to unlock shareholder value and strengthen DSS's position in the global pharmaceutical market by combining Dr. Ashleys' manufacturing prowess with Impact BioMedical's innovative platform.
DSS, Inc. (DSS, Financial) has announced a strategic reverse merger with Dr. Ashleys Limited, a global pharmaceutical company. The combined entity will be listed on NYSE American as "Dr Ashleys Limited," with DSS retaining a 4.80% ownership stake. The merger aims to unlock shareholder value and strengthen DSS's position in the global pharmaceutical market by combining Dr. Ashleys' manufacturing prowess with Impact BioMedical's innovative platform [1].The merger will involve a subsidiary of DSS, Impact BioMedical, merging with Dr. Ashleys through a reverse merger. This will result in the formation of a new publicly traded entity, Dr. Ashleys Limited, on the NYSE American. The primary goal of the merger is to integrate Dr. Ashleys' strengths in pharmaceutical manufacturing with Impact BioMedical's innovative platform to fast-track the development of new therapies.
Several actions are set to align and simplify ownership, enhancing DSS's strategic position in the new public company. This includes converting Impact's Series A Preferred Stock and exercising DSS's debt-to-equity rights. The shares involved, including those held by DSS, will be converted into ordinary shares of the new company, amounting to 4.80% of the total shares at closing.
The merger involves a subsidiary in Nevada merging with Impact, while simultaneously acquiring all shares of Dr. Ashleys Bio Labs Limited. Consequently, both Impact and Dr. Ashleys will become fully owned subsidiaries of the new entity. The management team from Dr. Ashleys will operate the company post-merger, with a new board of directors. The deal requires approval from Impact's shareholders, regulatory bodies, and the satisfaction of customary closing conditions, including SEC registration statements being declared effective and New York Stock Exchange listing approvals [1].
References:
[1] https://www.gurufocus.com/news/2942055/dss-subsidiary-impact-biomedical-enters-merger-agreement-with-dr-ashleys-dss-stock-news
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Incβs editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
ο»Ώ
No comments yet